Can this struggling stock turn things around?Ginkgo Bioworks (DNA -3.98%) is a cell programming company that claims to have large addressable markets (for bioengineered products) in multiple industries in which it can play a key role, and that those are worth trillions of dollars in total. But the problem is it may take more than a decade for those markets to reach that kind of size. Investors could require a lot of patience.While there may be a lot of potential for the business in the long run, investors h ...

A few enterprising businesses are marketing themselves differently.As you may have heard, there's a new trend in biotech lingo wherein companies call themselves "TechBio" rather than "biotech" to emphasize their forward-thinking about the role of information technology. Biotechs like Ginkgo Bioworks (DNA 2.63%), Recursion Pharmaceuticals (RXRX 6.01%), and Schrödinger (SDGR 0.30%) could easily be described by the term, and some, like Recursion, even describe themselves that way.But what does this new term ac ...

BOSTON, May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May. TD Cowen's 2nd Annual Sustainability Week: Ginkgo's Senior Director of Policy and Partnerships, Ryan Morhard, will participate in the virtual Sustainable API Manufacturing panel at 4:25 pm ET on May 22, 2024. Leerink Partners Healthcare Crossroads Conference: Ginkgo's Chief Bus ...

Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomyTOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with ...

财务数据和关键指标变化 - 第一季度Cell Engineering收入为2800万美元,同比下降18% [19] - Cell Engineering服务收入(不含下游价值分享)同比下降15%,主要由于早期客户收入下降,但大客户收入增长抵消了部分影响 [19] - 生物安全业务第一季度收入为1000万美元,毛利率为8% [21] - 研发费用(不含股份支付和并购相关费用)从2023年第一季度的1.09亿美元下降至2400万美元 [22] - 管理费用(不含股份支付和并购相关费用)从2023年第一季度的7100万美元下降至5100万美元 [23] - 调整后EBITDA为-1亿美元,与去年同期持平 [25] - 资本支出为700万美元,主要用于建设Biofab1设施 [26] 各条业务线数据和关键指标变化 - Cell Engineering业务新增17个细胞项目,总活跃项目达到140个,涉及82个客户,同比增长44% [19] - 生物安全业务正在持续建设国内外基础设施,特别是最近推出的Ginkgo Canopy和Ginkgo Horizon产品 [21] 各个市场数据和关键指标变化 - 公司客户群体广泛,涵盖农业、食品、工业、生物制药和消费生物技术等领域 [9] - 过去18个月内,公司新增了默克、诺和诺德、勃林格殷格翰和辉瑞等大型生物制药公司作为客户 [10] 公司战略和发展方向及行业竞争 - 公司将通过简化技术后端和前端服务条款来提高可扩展性和销售速度 [11][12] - 公司计划在2026年底前实现调整后EBITDA收支平衡 [15] - 公司将通过简化自动化平台和服务条款来提高效率和扩大客户群 [30][32][60] - 公司将专注于能够快速产生收入的项目,减少长期研发投入 [136][137] 管理层对经营环境和未来前景的评论 - 公司面临收入增长乏力但项目增加的问题,需要通过简化运营来提高效率 [13][20] - 公司目前现金充裕,没有银行债务,有足够的财务实力进行重组 [14][15] - 公司看好生物制药和人工智能领域的发展前景,认为可以为这些领域提供大规模数据支持服务 [65][66] 问答环节重要的提问和回答 问题1 **Rahul Sarugaser提问** 询问公司在当前行业环境下仍看好生物制造业务的原因,以及如何避免被归类为单纯的CDMO公司 [90][91] **Jason Kelly回答** - 公司客户群已从工业生物技术转向生物制药等领域,展现了平台的灵活性 [92][93][94] - 公司将通过提供大规模数据生成服务,而非单纯复制客户内部流程,来区别于传统CDMO [97][98][99] 问题2 **Matt Sykes提问** 询问公司未来将关注哪些关键绩效指标来衡量业务转型的成功 [104] **Mark Dmytruk回答** - 公司将重点关注现金流,以及实现2026年调整后EBITDA收支平衡为目标 [105][106][107] - 公司将评估新的商业模式对项目量和收入的影响,并适时调整相关指标 [107][108] 问题3 **Mike Ryskin提问** 询问公司如何确保在大幅削减成本的同时不会影响项目和收入规模 [120][121] **Jason Kelly回答** - 公司将优先保证对大型制药客户的服务,同时集中精力提高已有项目的自动化效率 [122][123][124][125][126][127][128][129][130][131] - 公司将减少一些长期研发投入,集中资源提高现有业务的交付能力 [134][135][136][137]

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.09, delivering no surprise.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Ginkgo Bioworks, which belongs t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________ FORM 10-Q ______________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commissio ...

Exhibit 99.1 Ginkgo Bioworks Reports First Quarter 2024 Financial Results Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026 Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024 BOSTON, Mass – May 9, 2024 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced it ...

The stock market has been on an incredible run over the past year with tech and growth stocks surging. Traders have piled into many fast-moving companies in hopes of locking in quick trading gains.This excitement has increasingly moved back into the meme stock arena as well. While meme stocks somewhat fell out of fashion in 2022 and 2023, they are firmly back now. Traders gravitate to companies with high short interest, lots of trading volume, and the possibility for rapid price movements.With interest rate ...

To scale up its production of brazzein, GreenLab will leverage its proprietary technology to grow proteins inside corn kernels, optimizing its process with Ginkgo's Plant Trait Services, Protein Services, and Deployment CapabilitiesJONESBORO, Ark. and BOSTON, May 7, 2024 /PRNewswire/ -- GreenLab, an emerging next generation plant-biotechnology company producing complex proteins in corn, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announ ...